Email Updates

Search form

You are here

What's Next for the Dapivirine Ring

March 30, 2018

Px Pulse Logo

In March, initial results from the two open-label trials of the dapivirine vaginal ring (HOPE and DREAM) showed that adherence and efficacy improved over the earlier Phase III trials. Open-label studies, unlike Phase III studies, do not use a placebo, and all participants know they are using an intervention with evidence of a certain level of HIV protection. The ring is also advancing along the pathway to licensure. If approved, it will be the next major prevention option available since the US FDA approved oral PrEP in 2012.

The dapivirine vaginal ring is made of silicone and inserted in the vagina releases the antiretroviral drug, dapivirine, over the course of a month to protect against HIV.

In this episode of Px Pulse, Zeda Rosenberg of the International Partnerships for Microbicides, which developed the ring, explains the latest findings and spells out how, when, where and if the ring might become an available tool. A trial participant and community leader in Uganda, Ruth*, pulls back the curtain on the ups and downs of using the ring, and a Ugandan investigator with the REACH study, Carolyne Akello of the Makere University-Johns Hopkins University Research Collaboration, explains the importance of the this trial, the next step in testing the potential of this monthly vaginal ring for young women.

*Last name withheld for confidentiality.

Listen to the full podcast here (30:40).

Highlights
Additional Resources
More Px Pulse

For more episodes of Px Pulse, click here.